Tyme reports Phase I data of SM-88 in metastatic cancer

Tyme Technologies Inc. (NASDAQ:TYME) reported data from an open-label Phase I trial in 30

Read the full 141 word article

How to gain access

Continue reading with a
two-week free trial.